3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
11
Leiomyosarcoma
2
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Brain Neoplasms
1
Interventions
Doxorubicin
19
Ifosfamide
12
Radiotherapy
11
pembrolizumab
6
Nivolumab
6
Ipilimumab
6
pazopanib
4
Specimen Handling
4
Radiation
4
Gemcitabine
4
Docetaxel
4
CTLA-4 Antigen
4
Biopsy
4
Trabectedin
3
Sunitinib
3
Magnetic Resonance Spectroscopy
3
pegfilgrastim
2
liposomal doxorubicin
2
cabozantinib
2
brostallicin
2
X-Rays
2
Radiotherapy, Conformal
2
Radiation Dose Hypofractionation
2
Methotrexate
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Diathermy
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
olaratumab
×
Sarcoma
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts